Category: Products

Paris, France and Camberley, UK – 15 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 12 March 2021 that, as at 11 March 2021, BlackRock Inc.’s holding in the Company on a voting and capital basis is 3% (2,119,828 shares). http://novacyt.com/wp-content/uploads/2021/03/Novacyt-BlackRock-holdings-15.03.2021-ENGLISH.pdf

Paris, France and Camberley, UK – 12 March 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 11 March 2021 that, as at 10 March 2021, BlackRock Inc.’s holding in the Company on a voting and capital basis is 2.99% (2,117,183 shares). http://novacyt.com/wp-content/uploads/2021/03/Novacyt-BlackRock-holdings-12.03.2021-ENGLISH.pdf

This is a correction to the Research and Development Update announcement published at 7:00am on 24 February 2021 (RNS number 1141Q) which has been amended with the following underlined additions to make it consistent with the French announcement released on Euronext at 8am CET on 24 February 2021. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-RD-Update-24.02.2021-correction-ENGLISH.pdf